Conformal Medical, a leading medical device company headquartered in Nashua, NH, has successfully raised $35 million in its Series D funding round. SPRIG Equity led the round, with participation from all major investors from the previous Series C round.
The significant investment will be instrumental in completing the clinical trial that aims to showcase the safety and effectiveness of Conformal Medical’s innovative solutions. These solutions are designed to address the unmet clinical needs in diagnosing and treating structural heart diseases, ultimately improving patient outcomes.
Founded in 2016 and under the guidance of CEO James Reinstein, Conformal Medical is at the forefront of developing medical devices specifically tailored to prevent stroke in patients with non-valvular atrial fibrillation (Afib). The company’s groundbreaking proprietary technology is poised to transform Left Atrial Appendage Occlusion (LAAO) procedures into efficient, same-day operations carried out by a single operator. With its CLAAS device, Conformal Medical aims to streamline the procedure by enabling off-axis positioning while ensuring a more uniform seal. Additionally, the CLAAS implant holds the potential to eliminate the need for procedural transesophageal echocardiograms, enabling physicians to perform the procedure without subjecting patients to general anesthesia.
The successful funding round stands as a testament to Conformal Medical’s remarkable progress and achievements, particularly in launching the CONFORM Clinical Trial. This pivotal trial evaluates the safety and efficacy of the CLAAS® System, comparing it to other commercially available LAAO devices. The trial’s outcomes will support the company’s pursuit of pre-market approval from the U.S. Food and Drug Administration (FDA). By sealing the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation (Afib), the CLAAS System holds the potential to significantly reduce the risk of stroke without necessitating anticoagulant use.
Conformal Medical’s relentless commitment to advancing stroke prevention in non-valvular Afib patients showcases their dedication to transforming the landscape of structural heart disease treatment. With their revolutionary technologies and ongoing clinical trials, Conformal Medical is paving the way for a future where patients receive improved care and enhanced quality of life.
